NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis $2.67 -0.26 (-8.87%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$2.67 0.00 (-0.07%) As of 10/30/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Editas Medicine Stock (NASDAQ:EDIT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Editas Medicine alerts:Sign Up Key Stats Today's Range$2.60▼$2.9250-Day Range$2.27▼$3.3052-Week Range$1.66▼$3.94Volume2.91 million shsAverage Volume2.47 million shsMarket Capitalization$410.06 millionP/E RatioN/ADividend YieldN/APrice Target$5.83Consensus RatingModerate Buy Company Overview Editas Medicine, Inc. is a biotechnology company focused on developing genomic medicines using CRISPR-based gene-editing technologies. The company’s research platforms include CRISPR/Cas9 and CRISPR/Cas12a, which are designed to make precise changes to DNA and potentially treat diseases caused by genetic abnormalities. Editas Medicine’s lead investigational program is reni-cel, formerly known as EDIT-301. Reni-cel is an ex vivo gene-editing therapy intended to treat sickle cell disease and transfusion-dependent beta thalassemia by modifying a patient’s blood-forming stem cells before they are returned to the body. The program is being evaluated in clinical studies, and the company continues to assess its safety and potential effectiveness. Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas Medicine conducts research and development activities aimed at addressing serious diseases with significant unmet medical needs. Its work is primarily focused on advancing gene-editing therapies through clinical development and potential commercialization in the United States and international markets.AI Generated. May Contain Errors. Read More Editas Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreEDIT MarketRank™: 2.447502282505 of 5 starsEditas Medicine scored higher than 49% of companies evaluated by MarketBeat, and ranked 639th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingEditas Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEditas Medicine has a consensus price target of $5.83, representing about 118.5% upside from its current price of $2.67.Amount of Analyst CoverageEditas Medicine has only been the subject of 4 research reports in the past 90 days.Read more about Editas Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($0.80) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 9.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Editas Medicine's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.66% of the float of Editas Medicine has been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 14.34, which indicates bearish sentiment.Change versus previous monthShort interest in Editas Medicine has recently increased by 2.90%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.76 News SentimentEditas Medicine has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Editas Medicine this week, compared to 4 articles on an average week.Search Interest2 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,109.00 in company stock.Percentage Held by Insiders3.10% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Editas Medicine's insider trading history. Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDIT Stock News HeadlinesGlobal Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and IntelliaOctober 29 at 3:07 PM | finance.yahoo.comEditas Medicine (NASDAQ:EDIT) Stock Breaks Above 200 Day Moving Average - Here's WhyOctober 29 at 3:21 AM | americanbankingnews.comCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This past May, flooding hit the same complex again, and in July Cigar Lake went down a second time, disrupting the world's largest high-grade uranium mine. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 1 at 1:00 AM | Digest Publishing (Ad)Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor ConferenceOctober 14, 2026 | finance.yahoo.comEditas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor ConferenceOctober 14, 2026 | globenewswire.comEditas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic ShiftOctober 12, 2026 | seekingalpha.comEDIT Set to Begin First-in-Human Study in HypercholesterolemiaOctober 9, 2026 | finance.yahoo.comEditas Medicine Receives Approval To Initiate Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In AustraliaOctober 9, 2026 | marketscreener.comMSee More Headlines EDIT Stock Analysis - Frequently Asked Questions How have EDIT shares performed this year? Editas Medicine's stock was trading at $2.05 on January 1st, 2026. Since then, EDIT shares have increased by 30.2% and is now trading at $2.67. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.12. The company had revenue of $11.89 million for the quarter, compared to the consensus estimate of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative trailing twelve-month return on equity of 196.63%. When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's top institutional shareholders include Profund Advisors LLC (0.04%), China Universal Asset Management Co. Ltd., ProShare Advisors LLC (0.02%) and Green Alpha Advisors LLC (0.02%). Insiders that own company stock include Gilmore Neil O'neill, Baisong Mei, Bruce Eaton, Jessica Hopfield, Linda Burkly and Amy Parison. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Micron Technology (MU) and Block (XYZ). Company Calendar Last Earnings8/05/2026Today11/01/2026Next Earnings (Estimated)11/09/20263rd Annual Guggenheim Healthcare Innovation Conference11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 5 days ago, EDIT's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EDIT CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees87Year Founded2013Price Target and Rating Average Price Target for Editas Medicine$5.83 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+118.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.06 million Net Margins-157.32% Pretax Margin-157.32% Return on Equity-196.63% Return on Assets-38.17% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio3.19 Sales & Book Value Annual Sales$40.52 million Price / Sales10.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book9.54Miscellaneous Outstanding Shares153,580,000Free Float148,819,000Market Cap$410.06 million OptionableOptionable Beta2.00 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:EDIT) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDIT Stock Alerts